Bristol-Myers Squibb has issued a `Dear Health Care Provider' letter advising of a change in the pregnancy category for Sustiva [efavirenz]

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1056, 2005-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Amgen Inc. has issued a `Dear Health Care Professional' letter advising of important changes to the labelling for Aranesp

By  

Reactions Weekly, Vol. 1, Iss. 1035, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Health Canada has granted a notice of compliance for Bristol-Myers Squibb's dasatinib [Sprycel] for use in patients with chronic myeloid leukaemia

By  

Inpharma, Vol. 1, Iss. 1582-1583, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

Bristol-Myers Squibb has announced that it will no longer make or sell the antidepressant Serzone

By  

Reactions Weekly, Vol. 1, Iss. 1007, 2004-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Health Canada has issued a `Dear Pharmacist' letter advising of a recall of certain sustained-release potassium replacement products

By  

Reactions Weekly, Vol. 1, Iss. 1018, 2004-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

The protease inhibitor atazanavir [Reyataz; Bristol-Myers Squibb] has been approved in the EU

By  

Inpharma, Vol. 1, Iss. 1430, 2004-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite